deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptide reconstitution is the process of dissolving a lyophilized peptide powder in a liquid solvent to produce a solution of defined concentration. Lyophilization removes water under vacuum from a frozen peptide solution, leaving a porous cake or powder. The dry form is often more stable for shipping and storage. Reconstitution restores the peptide to a liquid state for analytical, biochemical, or formulation work. The exact solvent depends on peptide sequence and intended assay.
Water is common, but not universal; hydrophobic peptides may require organic co-solvents like acetonitrile or dimethyl sulfoxide. Acidic peptides may dissolve better in dilute acetic acid or ammonium hydroxide, while basic peptides may favor slightly acidic conditions. Buffer choice matters because pH can affect charge, solubility, and aggregation. Some peptides require sonication or gentle mixing, whereas vigorous vortexing can cause foaming and surface denaturation. The target concentration is typically calculated from the labeled peptide mass and the volume of solvent added.
Cold storage slows most degradation but does not stop it. Reconstituted solutions are commonly divided into aliquots and held at -20 °C or -80 °C, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or precipitation, so single-use aliquots are preferred. Some peptides tolerate refrigeration for short intervals, while others require freezing immediately. Light-sensitive residues may need amber or foil-wrapped containers. The optimal condition remains peptide-specific and should be supported by stability data.
Analytical checks can detect changes in a reconstituted stock over time. Reverse-phase high-performance liquid chromatography can show loss of main peak, new impurity peaks, or altered retention. Mass spectrometry confirms molecular identity and can reveal modifications. Visual inspection for particles, color change, or turbidity provides a simple first check. If a solution shows signs of degradation or contamination, it is typically discarded rather than re-purified in a routine laboratory.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder or cake | Appearance varies from white to off-white with peptide sequence and fill. |
| Solubility class | Variable; often water-soluble | Hydrophobic sequences may require an organic co-solvent. |
| Common solvent | Sterile water or aqueous buffer | Choice depends on peptide charge and assay compatibility. |
| Typical pH range | 2 to 8 | Outside this range may accelerate degradation for some peptides. |
| Common analytical check | RP-HPLC | Confirms identity and purity after dissolution. |
Quality control for reconstituted peptides includes recording lot number, solvent, date, and storage conditions. Visual inspection checks clarity, color, and particles, while pH measurement verifies the expected solution environment. Concentration is often estimated by ultraviolet absorbance at 280 nm for peptides containing tryptophan or tyrosine, or by high-performance liquid chromatography. Mass spectrometry can confirm molecular identity before reconstitution. Sterility testing is relevant when microbial contamination would invalidate an experiment, though such testing is not routinely performed in every laboratory.
Once a peptide is dissolved, water becomes a medium for hydrolysis, oxidation, and deamidation. Dry powders often tolerate ambient shipping better than liquid solutions, but the exact stability profile depends on sequence and formulation. Refrigerated storage near 2 to 8 degrees Celsius or frozen storage at minus 20 or minus 80 degrees Celsius is common in laboratories. Repeated freeze-thaw cycles can promote aggregation, precipitation, or loss of activity. Dividing a solution into single-use aliquots before freezing can reduce the number of temperature cycles.
Aseptic technique is used when a reconstituted solution must remain free of microbial contamination. Work surfaces, gloves, and instruments are cleaned, and the septum of a vial is disinfected before solvent is added. A venting needle or pressure equalization can prevent aerosol formation and pressure buildup. Bacteriostatic water contains an antimicrobial preservative, but preservatives can interfere with some assays or alter peptide behavior. Sterile filtration may be used when a formulation cannot be heat sterilized or when particulates must be removed.
Practical handling often includes dividing a reconstituted solution into single-use aliquots to limit freeze-thaw cycling. Vials made of low-binding plastic or glass with inert closures are common, and some protocols add a carrier protein or bulking agent to reduce adsorption. Filtration through a sterile filter may be used when a sterile solution is required, but filters can retain peptide if binding occurs. Mixing is usually gentle; vigorous vortexing can introduce air-liquid interfaces that promote aggregation. Each of these steps involves trade-offs between sterility, recovery, and analytical accuracy.
Storage recommendations for reconstituted peptides vary by sequence and intended use, so general rules remain broad. A common laboratory practice is to keep solutions cold, sometimes frozen, and protected from light, but freezing itself can damage certain peptides. The pH of the solution may be adjusted to a range where the peptide is most stable, though changing pH can also alter solubility. Documentation of reconstitution date, solvent, concentration, and storage conditions supports reproducibility. Stability data for a specific peptide are generally established by direct measurement rather than assumed from related compounds.
Weapon No. 2, which underwent something other than normal release from the aircraft, evidenced by the fact that the parachute did not deploy, also had its arming rods extracted, and those components which were given the opportunity to act, did act in the manner expected. Full operation of this weapon was prevented by several things: Impact occurred so soon after separation of the Bisch rods that the timers were not given an opportunity to run down. The Arm/Safe Switch was in the "Safe" condition as the weapon left the aircraft. Another analysis by Sandia engineers in 1961 concluded that while in both weapons the MC-772 Arm/Safe Switch operated "as it was designed to do," the lanyard-controlled safing-pins "cannot be relied upon to prevent initiation of the fuzing sequence" in this kind of accident, and recommended implementing a modification to the weapons "as rapidly as possible" that would prevent the fuze power supply from activating except when live release was intended. A 1969 analysis by Sandia supervisor Parker F. Jones concluded that the Goldsboro accident illustrated that "the Mk 39 Mod 2 bomb did not possess adequate safety for the airborne alert role in the B-52."
Quantitative studies of enzymatic reactions often found that the acceleration of chemical reaction speed cannot be fully explained by existing theories like the approximation, acid/base catalysis and electrophile/nucleophile catalysis. And there is an obvious paradox: in reversible enzymatic reaction if the active site perfectly fits the substrates then the backward reaction will be slowed since products cannot fit perfectly into the active site. So conformational distortion was introduced and argues that both active site and substrate can undergo conformational changes to fit with each other all the time.
In 1988, Bio-Synthesis helped in the synthesis and characterization of a new class of peptides with novel antimicrobial properties discovered at the NIH. In 1989, OCS became incorporated as Bio-synthesis, Inc. and moved its laboratories to Lewisville, Texas. In 1993, Bio-Synthesis was one of the first peptide synthesis companies to acquire a Finnigan MALDI-TOF mass spectrometer for the accurate quality control of synthetic peptides produced in-house. In 1994, Bio-synthesis pioneered the use of molecular methods for HLA analysis which is applied in organ matching for transplantation purposes. Later in the same year Bio-Synthesis held the first major HLA DNA typing workshop with the attendance of HLA laboratory directors from around the country in conjunction with University of North Texas in Denton Texas.
Calmodulin-like protein 5 is a protein that in humans is encoded by the CALML5 gene. This gene encodes a novel calcium binding protein expressed in the epidermis and related to the calmodulin family of calcium binding proteins. Functional studies with recombinant protein demonstrate it does bind calcium and undergoes a conformational change when it does so. Abundant expression is detected only in reconstructed epidermis and is restricted to differentiating keratinocytes. In addition, it can associate with transglutaminase 3, shown to be a key enzyme in the terminal differentiation of keratinocytes. Human CALML5 genome location and CALML5 gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: Q9NZT1 (Human Calmodulin-like protein 5) at the PDBe-KB.
Sources: en.wikipedia.org
BC Research Inc. is a privately owned Canadian process technology incubator, specializing in custom research, process development and technology commercialization. Headquartered in Vancouver, British Columbia, BC Research operates primarily from their Technology Commercialization and Innovation Centre on Mitchell Island in the Vancouver suburb of Richmond. This 40,000 sq-ft facility includes a 28,000 sq-ft pilot plant development area, 2,500 sq-ft laboratory space, 9,000 sq-ft of office space, as well as a small machine shop and fenced outdoor piloting space. Technologies are scaled up from concept to pilot or demonstration scale in preparation for commercialization. Engineering support is provided by sister companies NORAM Engineering and Constructors Ltd. Previously, BC Research was located at the BC Research and Innovation Complex at the south end of the University of British Columbia campus. This facility closed in November 2007. The company specialized in consulting and applied research and development in the area of plant biotechnology and environment, health and safety, process and analysis, transportation and ship dynamics.
Projected to go undrafted by Sports Illustrated, who criticized his lack of "balance, body control and ability in space," Kuper was ranked as the No. 28 offensive guard available in the 2006 NFL draft. Kuper was eventually selected in the fifth round, 161st overall, by the Denver Broncos. He was the highest selected North Dakota lineman since Todd Thomas in 1981. Kuper started 79-of-90 games played (68 at right guard) while playing his entire eight-year NFL career with the Broncos. On June 4, 2010, the Broncos announced that they had signed Kuper to a five-year deal worth $25.5 million. The new contract made him the second-highest-paid offensive lineman in Broncos' history, second only to former left tackle Matt Lepsis. In 2010, the Denver Broncos announced that Kuper had been selected as co-captain of the Broncos offense, along with Kyle Orton and Daniel Graham. During the regular season finale in 2011 against the Kansas City Chiefs, Kuper suffered a gruesome broken ankle that ended his season. That season Kuper made the Pro Bowl, but withdrew due to the injury and needed surgery. A three-time captain, Kuper was recipient of the Ed Block Courage Award in 2012 as voted on by his teammates. Kuper retired on March 11, 2014.
Ectopic fat is the storage of triglycerides in tissues other than adipose tissue, that are supposed to contain only small amounts of fat, such as the liver, skeletal muscle, heart, and pancreas. This can interfere with cellular functions and hence organ function and is associated with insulin resistance in type 2 diabetes. It is stored in relatively high amounts around the organs of the abdominal cavity, but is not to be confused with visceral fat. The specific cause for the accumulation of ectopic fat is unknown. The cause is likely a combination of genetic, environmental, and behavioral factors that are involved in excess energy intake and decreased physical activity. Substantial weight loss can reduce ectopic fat stores in all organs and this is associated with an improvement of the function of those organs. In the latter case, non-invasive weight loss interventions like diet or exercise can decrease ectopic fat (particularly in heart and liver) in overweight or obese children and adults.
Gs exerts its effects via two pathways. Firstly, it directly opens L-type calcium channels (LTCC) in the plasma membrane. Secondly, it renders adenylate cyclase activated, resulting in an increase of cAMP, activating protein kinase A (PKA) which in turn phosphorylates several targets, such as phospholamban, LTCC, Troponin I (TnI), and potassium channels. The phosphorylation of phospholamban deactivates its own function which normally inhibits SERCA on the sarcoplasmic reticulum (SR) in cardiac myocytes. Due to this, more calcium enters the SR and is therefore available for the next contraction. LTCC phosphorylation increases its open probability and therefore allows more calcium to enter the myocyte upon cell depolarisation. Both of these mechanisms increase the available calcium for contraction and therefore increase inotropy. Conversely, TnI phosphorylation results in its facilitated dissociation of calcium from troponin C (TnC) which speeds the muscle relaxation (positive lusitropy). Potassium channel phosphorylation increases its open probability which results in shorter refractory period (because the cell repolarises faster), also increasing lusitropy. Furthermore, in nodal cells such as in the SA node, cAMP directly binds to and opens the HCN channels, increasing their open probability, which increases chronotropy.
HCl(aq) + NaOH(aq) → H2O(l) + NaCl(aq) Neutralization is the basis of titration, where a pH indicator shows equivalence point when the equivalent number of moles of a base have been added to an acid. It is often wrongly assumed that neutralization should result in a solution with pH 7.0, which is only the case with similar acid and base strengths during a reaction. Neutralization with a base weaker than the acid results in a weakly acidic salt. An example is the weakly acidic ammonium chloride, which is produced from the strong acid hydrogen chloride and the weak base ammonia. Conversely, neutralizing a weak acid with a strong base gives a weakly basic salt (e.g., sodium fluoride from hydrogen fluoride and sodium hydroxide).
Sources: en.wikipedia.org
Lyophilized peptide is a dry powder made by freeze-drying, while reconstituted peptide is dissolved in a solvent. The dry form generally offers longer storage at appropriate temperatures. Reconstitution introduces water and increases the risk of degradation.
No single solvent works for all peptides. The choice depends on sequence, charge, hydrophobicity, and assay compatibility. Water, aqueous buffers, and organic co-solvents are common, but each can alter peptide behavior.
Not always. Some peptides are supplied as pre-dissolved solutions or in formulations ready for a specific assay. Reconstitution is mainly needed when the supplied form is a lyophilized powder, and the required format depends on the intended application.
No single time applies to all peptides. Storage life depends on sequence, solvent, concentration, and temperature. Stability should be determined experimentally or taken from supplier data for the specific lot.